Market Overview

HeartSciences Showcases MyoVista® Wavelet ECG at 2018 European Society of Cardiology Congress (ESC)


Hall A, Booth G320

a medical device company developing next generation ECG devices using
continuous wavelet transform (CWT) signal processing and artificial
intelligence, is proud to announce its participation as an exhibitor at
the upcoming 2018 European Society of Cardiology Congress (ESC). The
Congress will take place at Messe Munich International in Munich,
Germany and will run from August 25 to August 29, 2018. HeartSciences
will highlight its MyoVista® Wavelet ECG (wavECG™) Cardiac
Testing Device as well as recent clinical study results published in the
Journal of the American College of Cardiology (JACC)

This press release features multimedia. View the full release here:

MyoVista Wavelet ECG 12-Lead Cardiac Testing Device (Photo: Business Wire)

MyoVista Wavelet ECG 12-Lead Cardiac Testing Device (Photo: Business Wire)

The JACC article titled "Prediction of Abnormal Myocardial Relaxation
from Signal Processed Surface ECG
" presented the results from the
investigator-initiated clinical study that focused on evaluating the
feasibility of MyoVista®
Wavelet ECG as a diagnostic tool for predicting myocardial relaxation
abnormalities. Results from the study demonstrate MyoVista's patented
technology based on CWT signal processing can detect myocardial
relaxation abnormalities associated with LVDD.

About HeartSciences

is advancing the field of electrocardiography through the application of
wavelet signal processing and artificial intelligence to develop next
generation ECG technology. Wavelet signal processing is currently used
in many different industries as an important tool to provide insights
and new valuable data related to spectral analysis of a signal.
HeartSciences' MyoVista
Cardiac Testing Device is a 12-lead resting
electrocardiograph utilizing continuous wavelet transform (CWT) based
signal processing. Patented informatics focus on energy related
information rather than conventional voltage-based information.
HeartSciences mission is to enable accurate, affordable screening for
the early detection of heart disease.

In addition to the proprietary informatics, the MyoVista wavECG
Device also features the capabilities of a full featured 12-lead resting
ECG including analysis using the Glasgow Algorithm, one of the world's
most respected interpretive algorithms. The device has a 15.6-inch
high-resolution touchscreen display and incorporates many features
commonly associated with a tablet device requiring minimal user training
as well as easy and intuitive use. The MyoVista wavECG Device is
not currently approved for sale or distribution in the United States and
is not currently FDA cleared.

is a privately-held U.S. corporation based in Southlake, Texas.

For more information visit

View Comments and Join the Discussion!